{"schema_version":"secwatch.filing_event.v1","accession":"0001935979-26-000022","form_type":"8-K","ticker":"BHVN","cik":"0001935979","company_name":"Biohaven Ltd.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.819712+00:00","generated_at":"2026-05-15T22:48:36.531620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biohaven reports Q4 loss $145.6M, prioritizes three late-stage programs, raises $178.9M","bullets":["Q4 net loss $145.6M ($1.21/sh); non-GAAP adj. net loss $107.9M ($0.90/sh).","Cash, equivalents, securities $322M at year end; raised $178.9M via 17.2M share issuance.","Pivotal trial for IgAN degrader BHV-1400 starts Q1 2026; Graves' degrader BHV-1300 pivotal in 2H 2026.","Opakalim OLE: >50% seizure reduction in most on 75mg at 6 months; pivotal data due 2H 2026.","Taldefgrobep Phase 2 obesity initiated Q4 2025; topline results expected 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001935979-26-000022","json":"https://secwatch.observer/filing/0001935979-26-000022.json","markdown":"https://secwatch.observer/filing/0001935979-26-000022.md","text":"https://secwatch.observer/filing/0001935979-26-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000022/0001935979-26-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000022/bhvn-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:48:36.531620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}